Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Neuroscience ; 241: 157-69, 2013 Jun 25.
Artigo em Inglês | MEDLINE | ID: mdl-23531437

RESUMO

Elevated nerve growth factor (NGF) is believed to play a role in many types of pain. An NGF-blocking antibody (muMab 911) has been shown to reduce pain and hyperalgesia in pain models, suggesting a novel therapeutic approach for pain management. Since NGF also plays important roles in peripheral nervous system development and sensory nerve outgrowth, we asked whether anti-NGF antibodies would adversely impact peripheral nerve regeneration. Adult rats underwent a unilateral sciatic nerve crush to transect axons and were subcutaneously dosed weekly for 8weeks with muMab 911 or vehicle beginning 1day prior to injury. Plasma levels of muMab 911 were assessed from blood samples and foot print analysis was used to assess functional recovery. At 8-weeks post-nerve injury, sciatic nerves were prepared for light and electron microscopy. In a separate group, Fluro-Gold was injected subcutaneously at the ankle prior to perfusion, and counts and sizes of retrogradely labeled and unlabeled dorsal root ganglion neurons were obtained. There was no difference in the time course of gait recovery in antibody-treated and vehicle-treated animals. The number of myelinated and nonmyelinated axons was the same in the muMab 911-treated crushed nerves and intact nerves, consistent with observed complete recovery. Treatment with muMab 911 did however result in a small decrease in average cell body size on both the intact and injured sides. These results indicate that muMab 911 did not impair functional recovery or nerve regeneration after nerve injury in adult rats.


Assuntos
Anticorpos Monoclonais/farmacologia , Fator de Crescimento Neural/antagonistas & inibidores , Regeneração Nervosa/fisiologia , Recuperação de Função Fisiológica/efeitos dos fármacos , Nervo Isquiático/fisiologia , Envelhecimento , Animais , Ensaio de Imunoadsorção Enzimática , Feminino , Compressão Nervosa , Regeneração Nervosa/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Nervo Isquiático/lesões
2.
Clin Cancer Res ; 6(7): 2677-84, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10914709

RESUMO

Glycinamide ribonucleotide formyltransferase (GARFT) is a component of the de novo purine synthesis pathway. AG2034 is a specific inhibitor of GARFT that was designed based on the GARFT crystal structure. In conjunction with Phase I studies at four clinical centers in the United States and United Kingdom, AG2034 pharmacology was evaluated in 54 patients receiving 1-11 mg/m2 AG2034 as a 2-5 min injection. Blood samples were obtained just prior to and 5, 15, 30, and 45 min, and 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, and 96 h after bolus injection during course 1. Limited sampling was also performed on course 3. Plasma AG2034 was measured using a sensitive and reproducible ELISA assay. AG2034 demonstrated a trimodal elimination pattern over 24 h, with median half-life (t(1/2))alpha = 8.7 min, t(1/2)beta = 72.6 min, and t(1/2)gamma = 364.2 min. AG2034 systemic clearance ranged from 9.4-144.5 ml/min/m2, and volume of distribution was 1.2-7.6 liters/m2. Course 1 AG2034 area under the concentration versus time curve (AUC) had a linear relationship with dose (r(s) = 0.86). Accumulation of AG2034 was evident, because course 3 AUC was higher than course 1 in 23 of 23 evaluable patients, but was not associated with an increase in erythrocyte AG2034. AG2034 systemic exposure had an impact on toxicity, because course 1 and course 3 AG2034 AUCs were significantly higher for patients with grade III/IV toxicity than patients with less than grade II toxicity (P < 0.001 and P = 0.001 for course 1 and course 3, respectively). This study demonstrates rapid systemic clearance of AG2034 and suggests pharmacokinetic approaches that may minimize patient toxicity and aid the development of this interesting class of anticancer agents.


Assuntos
Antineoplásicos/efeitos adversos , Antineoplásicos/farmacocinética , Glutamatos/efeitos adversos , Glutamatos/farmacocinética , Neoplasias/tratamento farmacológico , Pirimidinas/efeitos adversos , Pirimidinas/farmacocinética , Adulto , Idoso , Antineoplásicos/administração & dosagem , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/farmacocinética , Feminino , Glutamatos/administração & dosagem , Humanos , Hidroximetil e Formil Transferases/antagonistas & inibidores , Infusões Intravenosas , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Fosforribosilglicinamido Formiltransferase , Pirimidinas/administração & dosagem , Análise de Regressão , Reino Unido , Estados Unidos
3.
Oncol Res ; 8(7-8): 273-9, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8938790

RESUMO

Human colon tumor cell lines that were adapted to grow in chemically defined medium were tested for their growth sensitivity to exogenous transferrin, insulin, and epidermal growth factor (EGF). Less differentiated cell lines, C and HCT116, were able to grow in the presence of a single peptide supplement, to respond synergistically to transferrin and insulin in combination, and to be insensitive to supplementation with exogenous EGF. The more differentiated cell lines, CBS and GEO, were found to respond to exogenous EGF in a concentration-dependent manner, to require at least two peptide factor supplements to support growth, and to respond synergistically when EGF was added to chemically defined medium that already contained transferrin and insulin. To investigate whether changes in the number or the affinity-classes of the EGF-receptor might be involved in any of these growth responses, changes in EGF-receptor number and dissociation constant were determined as a function of cell growth condition. The poorly differentiated HCT cell line HCT116 was found to undergo 28 to 64% increases in [125I]EGF-binding when its medium was supplemented with transferrin, insulin, or transferrin plus insulin. The more differentiated CBS cell line responded to all peptide supplements with decreases in [125I]EGF-binding ranging from 12 to 73%. These findings indicate that the actions of transferrin and insulin are fundamental to the growth regulatory mechanisms of these two differentiation classes of human colon tumor cell lines, but that their mechanisms are different.


Assuntos
Adenocarcinoma/patologia , Neoplasias do Colo/patologia , Insulina/farmacologia , Transferrina/farmacologia , Diferenciação Celular/efeitos dos fármacos , Meios de Cultura Livres de Soro , Sinergismo Farmacológico , Fator de Crescimento Epidérmico/farmacologia , Humanos , Células Tumorais Cultivadas/efeitos dos fármacos
4.
J Cell Physiol ; 157(2): 253-62, 1993 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8227158

RESUMO

Although the biologic response modifier tumor necrosis factor-alpha (TNF) is a known differentiation inducer in hematopoietic cells, its role in differentiation of other tissue types has yet to be elucidated. In the studies presented here, TNF treatment of the human rectal adenocarcinoma cell line, DiFi, elicits characteristics of early stage differentiating, mucin-producing colonocytes. Not only are TNF-treated DiFi cells growth-inhibited by TNF, but they also display a unique morphology. Additionally, TNF treatment of DiFi cells enhances > fivefold the expression of high molecular weight mucin glycoproteins, as measured by [125I]-wheat germ agglutinin (WGA) binding and the human milk fat globule-1 (HMFG-1) anti-MUC1 antibody reactivity. The induction of these differentiation characteristics correlates with novel alterations in epidermal growth factor receptor (EGF-R). Following 5-day TNF treatment of DiFi cultures, EGF receptor levels, kinase autophosphorylation activity, and receptor tyrosine phosphorylation are reduced by > fourfold. The establishment of a model system in which goblet-like cell characteristics and alterations in a growth factor receptor can be induced in vitro may be potentially useful in studying the underlying mechanisms of colonic epithelial cell proliferation and differentiation.


Assuntos
Adenocarcinoma/patologia , Transformação Celular Neoplásica/patologia , Regulação para Baixo/fisiologia , Receptores ErbB/fisiologia , Neoplasias Retais/patologia , Fator de Necrose Tumoral alfa/farmacologia , Adenocarcinoma/química , Adenocarcinoma/ultraestrutura , Northern Blotting , Divisão Celular/efeitos dos fármacos , Transformação Celular Neoplásica/genética , Regulação para Baixo/genética , Receptores ErbB/análise , Receptores ErbB/genética , Humanos , Radioisótopos do Iodo , Glicoproteínas de Membrana/metabolismo , Mucina-1 , Mucinas/análise , Mucinas/metabolismo , Fenótipo , Testes de Precipitina , Neoplasias Retais/química , Neoplasias Retais/ultraestrutura , Fatores de Tempo , Células Tumorais Cultivadas , Aglutininas do Germe de Trigo/metabolismo
5.
Exp Cell Res ; 206(1): 49-57, 1993 May.
Artigo em Inglês | MEDLINE | ID: mdl-8482359

RESUMO

Transforming growth factor-alpha (TGF alpha) is able to elicit growth in many target cells expressing a functional epidermal growth factor (EGF) receptor. Other laboratories have reported that the TGF alpha precursor polypeptide (proTGF alpha) is inefficiently cleaved from many target cells, resulting in accumulation of proTGF alpha on the cell surface. Since it has been shown that noncleavable, mutated cell-associated TGF alpha can stimulate cell growth on receptor-bearing adjacent cells, we have tried to determine whether cell-associated TGF alpha populations might be involved in supporting autonomous cell growth regulatory mechanisms in a human colon carcinoma cell line, HCT116. To address this question, the levels of secreted and nonsecreted TGF alpha produced were determined. Cells grown to medium cell density (40-60% confluent) expressed the greatest percentage of cell-associated TGF alpha (50%). Incubation of HCT116 cells with 0.1 U/ml porcine pancreatic elastase resulted in the release of 67% of the cell-associated TGF alpha into their medium and caused the treated cells to acquire a newly established growth sensitivity to exogenous TGF alpha at a ligand concentration of 1.0 nM. Western blot analysis of EGF receptor phosphotyrosine levels showed a decrease in phosphotyrosine content after elastase treatment. Phosphotyrosine content was restored to basal levels if elastase treatment was followed by addition of exogenous TGF alpha or EGF. These results suggest that HCT116 cells use a "closed" autocrine loop between cell-associated TGF alpha species and their EGF receptor to stimulate their cell growth.


Assuntos
Neoplasias do Colo/patologia , Fator de Crescimento Transformador alfa/fisiologia , Western Blotting , Contagem de Células , Divisão Celular/fisiologia , Neoplasias do Colo/química , Neoplasias do Colo/ultraestrutura , Receptores ErbB/análise , Receptores ErbB/metabolismo , Receptores ErbB/fisiologia , Humanos , Elastase Pancreática/farmacologia , Fosforilação/efeitos dos fármacos , Testes de Precipitina , Proteínas Recombinantes/farmacologia , Fator de Crescimento Transformador alfa/análise , Fator de Crescimento Transformador alfa/metabolismo , Células Tumorais Cultivadas
6.
Cancer Res ; 53(7): 1630-6, 1993 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-8453634

RESUMO

The DiFi colorectal carcinoma cell line, derived from a patient with familial adenomatous polyposis, was examined for gene expression and production of the autocrine growth factor transforming growth factor alpha (TGF-alpha) and for epidermal growth factor receptor (EGFR) gene expression and gene copy number. DiFi cells expressed TGF-alpha transcripts as identified on Northern (RNA) blots. Addition of TGF-alpha (10 ng/ml) or EGF (10 ng/ml) to DiFi cell cultures (lacking EGF or serum) up-regulated DiFi cell basal TGF-alpha mRNA levels, suggesting that autoinduction of TGF-alpha occurs in these cells. DiFi cell cultures in log phase growth secreted measurable amounts of TGF-alpha (347 pg/10(6) cells/24 h) into their culture medium, as determined by radioimmunoassay. DiFi cells showed strong overexpression of the EGFR gene on Northern blots relative to three other colon cancer cell lines examined. Immunoperoxidase staining showed enhanced EGFR expression in a cell subpopulation among the original (uncultured) ascitic fluid cells from which the DiFi cell line was established. This cell subpopulation was observed to expand dramatically between passages 1 and 25. Immune complex kinase assay of DiFi cells showed that EGFR were functional as determined by their ability to autophosphorylate. The EGFR gene in these cells was not found to be rearranged or genetically altered using Southern blot analysis. Dot blot analysis of DiFi cell DNA revealed EGFR gene amplification in the range of 60-80 copies/cell, which is approximately twice the copy number seen in A-431 epidermoid carcinoma cells. To our knowledge DiFi cells represent the first example of EGFR gene amplification in a colorectal adenocarcinoma. Because DiFi colorectal cancer cells uniquely show production and auto-induction of TGF-alpha in addition to amplification and overexpression of the EGFR gene, these cells represent a valuable tool for studying the role(s) of the EGFR in the regulation of tumor cell growth.


Assuntos
Neoplasias Colorretais/metabolismo , DNA de Neoplasias/análise , Receptores ErbB/genética , Amplificação de Genes/genética , Fator de Crescimento Transformador alfa/biossíntese , Northern Blotting , Southern Blotting , Receptores ErbB/análise , Receptores ErbB/metabolismo , Humanos , Fosforilação , Células Tumorais Cultivadas , Regulação para Cima
7.
Cancer Res ; 51(5): 1452-9, 1991 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-1847663

RESUMO

The receptor binding and cellular growth responses to exogenous epidermal growth factor (EGF) were studied using the DiFi cell line established from a familial adenomatous polyposis patient. The number of cell membrane EGF receptors on DiFi cells, as measured by competitive radioligand binding assays and Scatchard analysis of 125I-EGF binding isotherms, was calculated to be 4.8 x 10(6) receptors/cell. An acid prewash step performed prior to ligand binding assays did not reveal additional receptor numbers. A single, low-affinity receptor population was identified by Scatchard analysis, with an apparent Kd of 4.6 nM. This result was confirmed by radioligand binding studies performed in the presence and absence of the receptor-antagonist monoclonal antibody 528 IgG that binds predominantly to the low-affinity form of the EGF receptor. DiFi cells at 50-60% confluence, when exposed to 50 nM exogenous EGF, exhibited a rapid but partial (30%) reduction in their cell membrane-associated receptor, characteristic of sequestration. Exposure of DiFi cells to 50 nM EGF for longer periods of time (4 h) did not result in any further reduction in EGF-receptor number. The cellular growth response of DiFi cells to exogenous EGF was studied in monolayer cultures as well as in a soft agarose assay. Inhibition of soft agar colony formation was observed at exogenous EGF concentrations greater than 1.7 nM, and inhibition of monolayer growth occurred at EGF concentrations greater than 1 nM. In immune complex kinase assays, the DiFi receptor showed similar specific activity to that from the well-characterized A431 cell line. Additionally, phosphorylation of the receptor on tyrosine was qualitatively similar to that of A431 cells, further suggesting that the DiFi receptors identified by EGF-binding studies were biologically functional.


Assuntos
Polipose Adenomatosa do Colo/metabolismo , Carcinoma/química , Neoplasias do Colo/química , Fator de Crescimento Epidérmico/farmacologia , Receptores ErbB/análise , Polipose Adenomatosa do Colo/patologia , Anticorpos Monoclonais/imunologia , Carcinoma/patologia , Neoplasias do Colo/patologia , Relação Dose-Resposta a Droga , Fator de Crescimento Epidérmico/metabolismo , Receptores ErbB/fisiologia , Humanos , Fosforilação , Proteínas Tirosina Quinases/análise , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA